US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CLIMB BIO INC

1.27

-0.0300-2.31%

Post-market: 1.270.00000.00%19:58 EDT

Volume:241.65K

Turnover:303.00K

Market Cap:85.69M

PE:-0.83

High:1.37

Open:1.30

Low:1.23

Close:1.30

Loading ...

Overview Company News Filings

Climb Bio Signs Deal With Beijing Mabworks Biotech to Develop Antibody for IgA Nephropathy

MT Newswires Live

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the April Pathway for Iga Nephropathy

THOMSON REUTERS

Climb Bio Inc: Preclinical Data Expected to Be Shared Later in 2025

THOMSON REUTERS

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Climb Bio to Join Nasdaq Biotechnology Index

MT Newswires Live

BRIEF-Climb Bio To Be Added To The Nasdaq Biotechnology Index

Climb Bio to be added to Nasdaq Biotechnology Index

Climb Bio to Be Added to the Nasdaq Biotechnology Index

THOMSON REUTERS

Climb Bio Inc - Inclusion in Nasdaq Biotech Index Effective Prior to Market Open on December 23, 2024

THOMSON REUTERS

BRIEF-Climb Bio Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing

Climb Bio Q3 EPS $(0.13) Up From $(0.15) YoY

Climb Bio Inc Files for Mixed Shelf of up to $200 Mln - SEC Filing

THOMSON REUTERS

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Climb Bio Names Douglas Williams Board Chair

MT Newswires Live

Climb Bio Appoints Douglas E. Williams, Ph.d., as Chair of the Board

THOMSON REUTERS

Climb Bio Inc - Andrew Levin to Remain on Board, Liam Ratcliffe Steps Down

THOMSON REUTERS

Press Release: Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CLYM/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CLYM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":1.27,"timestamp":1745611200000,"preClose":1.3,"halted":0,"volume":241645,"hourTrading":{"tag":"盘后","latestPrice":1.27,"preClose":1.27,"latestTime":"19:58 EDT","volume":996,"amount":1265.27,"timestamp":1745625499287},"delay":0,"floatShares":30642992,"shares":67475395,"eps":-1.5343,"marketStatus":"Market Closed","change":-0.03,"latestTime":"04-25 16:00:00 EDT","open":1.3,"high":1.37,"low":1.23,"amount":303001.56523999997,"amplitude":0.107692,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.5343,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":1.3,"postHourTrading":{"tag":"盘后","latestPrice":1.27,"preClose":1.27,"latestTime":"19:58 EDT","volume":996,"amount":1265.27,"timestamp":1745625499287},"volumeRatio":3.0233098709316124},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CLYM\",,,,,undefined,":{"symbol":"CLYM","floatShares":30642992,"roa":"-10.30%","roe":"-46.26%","lyrEps":-1.5343,"volumeRatio":3.0233098709316124,"shares":67475395,"dividePrice":0,"high":1.37,"amplitude":0.107692,"preClose":1.3,"low":1.23,"week52Low":1.05,"pbRate":"0.40","week52High":11.55,"institutionHeld":0,"latestPrice":1.27,"eps":-1.5343,"divideRate":0,"volume":241645,"delay":0,"ttmEps":-1.5343,"open":1.3,"prevYearClose":1.8,"prevWeekClose":1.26,"prevMonthClose":1.22,"prevQuarterClose":1.22,"fiveDayClose":1.26,"twentyDayClose":1.27,"sixtyDayClose":1.93},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CLYM\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2502047979","title":"Climb Bio Signs Deal With Beijing Mabworks Biotech to Develop Antibody for IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2502047979","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502047979?lang=en_us&edition=fundamental","pubTime":"2025-01-10 01:27","pubTimestamp":1736443627,"startTime":"0","endTime":"0","summary":"Climb Bio  said Thursday it has signed an exclusive licensing deal with Beijing Mabworks Biotech to develop and commercialize anti-APRIL monoclonal antibody CLYM116 outside of Greater China to potentially treat patients with IgA nephropathy and other B-cell-mediated diseases.Under the agreement, Climb Bio said it will pay $9 million upfront to Mabworks and make milestone payments as well as low- to mid-single-digit royalties on net sales outside of Greater China.Climb Bio said it is conducting preclinical studies on CLYM116 and expects to share data later in 2025.Additionally, the company said it had about $212.9 million in cash, cash equivalents and short-term marketable securities as of Dec. 31, which is expected to fund operations through 2027.Price: 1.87, Change: -0.22, Percent Change: -10.53","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2502201535","title":"Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the April Pathway for Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2502201535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502201535?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:00","pubTimestamp":1736424051,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nFWN3O50E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2502015357","title":"Climb Bio Inc: Preclinical Data Expected to Be Shared Later in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502015357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502015357?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:00","pubTimestamp":1736424051,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nFWN3O50E5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2502019907","title":"Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2502019907","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502019907?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:00","pubTimestamp":1736424000,"startTime":"0","endTime":"0","summary":"Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases. New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs. Preclinical Data Expected to be Shared Later in 2025. \"Adding CLYM116 to our pipeline represents a pivotal moment for Climb Bio as we advance our ambition of becoming a leader in developing best-in-class treatments for patients with immune-mediated diseases,\" said Aoife Brennan, President and CEO of Climb Bio. \"IgA nephropathy is the most common cause of glomerulonephritis worldwide, and we believe that inhibition of APRIL is both a clinically validated mechanism and potentially disease modifying approach for this indication. We look forward to rapidly advancing CLYM116 and sharing initial preclinical data later in 2025.\". Transaction DetailsUnder the terms of the agreement, Climb Bio will make an upfront cash payment of $9 million to Mab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/climb-bio-expands-pipeline-exclusive-120000545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2492613170","title":"Climb Bio to Join Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492613170","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492613170?lang=en_us&edition=fundamental","pubTime":"2024-12-19 23:47","pubTimestamp":1734623250,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM) said Thursday it will be added to the Nasdaq Biotech Index as part of the annual reconstitution of the stock exchange's indexes.The company's inclusion in the index will be effective before market open on Monday, the company said.Price: 1.92, Change: -0.11, Percent Change: -5.19","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":[".IXIC","BK4588","CLYM","LU2095319765.USD","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","NQmain","BK4585","NDAQ","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2492244124","title":"BRIEF-Climb Bio To Be Added To The Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492244124","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492244124?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:34","pubTimestamp":1734611660,"startTime":"0","endTime":"0","summary":"BRIEF-Climb Bio To Be Added To The Nasdaq Biotechnology IndexDec 19 (Reuters) - Climb Bio Inc CLYM.O:CLIMB BIO TO BE ADDED TO THE NASDAQ BIOTECHNOLOGY INDEXCLIMB BIO INC - INCLUSION IN NASDAQ BIOTECH ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUAZQTJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NDAQ","IE00BKPKM429.USD","IE00B64PRP62.GBP","CLYM","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","BK4139","BK4588"],"gpt_icon":0},{"id":"2492012441","title":"Climb Bio to be added to Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492012441","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492012441?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:15","pubTimestamp":1734610556,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM) announced that the company will be added to the NASDAQ Biotech Index (NBI) as part of the annual reconstitution of the 2024 Nasdaq...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/climb-bio-to-be-added-to-nasdaq-biotechnology-index?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/climb-bio-to-be-added-to-nasdaq-biotechnology-index?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SQQQ","QLD","QQQ","NVIW.SI","CLYM","LU2095319765.USD","MNQmain","USJW.SI","IE00B3QW5Z07.USD","NQmain","BK4588","TQQQ","BK4112","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","LU2210150020.SGD","TSYW.SI","NDAQ","BK4139","QID","IE00BKPKM429.USD","IE00BGHQF748.EUR","USAW.SI","PSQ",".IXIC"],"gpt_icon":0},{"id":"2492129152","title":"Climb Bio to Be Added to the Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492129152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492129152?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:00","pubTimestamp":1734609601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUAZQTJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4112","NDAQ","LU2210150020.SGD","LU2095319765.USD","CLYM","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","IE00BKPKM429.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2492129073","title":"Climb Bio Inc - Inclusion in Nasdaq Biotech Index Effective Prior to Market Open on December 23, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2492129073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492129073?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:00","pubTimestamp":1734609601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUAZQTJZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4112","LU2210150020.SGD","NDAQ","BK4139","BK4585","CLYM","IE00BKPKM429.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2483625990","title":"BRIEF-Climb Bio Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483625990","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483625990?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:22","pubTimestamp":1731453756,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - Climb Bio Inc   :   * CLIMB BIO INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4008","UP","CLYM","BK4139"],"gpt_icon":0},{"id":"2483657280","title":"Climb Bio Q3 EPS $(0.13) Up From $(0.15) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2483657280","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483657280?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:15","pubTimestamp":1731449707,"startTime":"0","endTime":"0","summary":"Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41923529/climb-bio-q3-eps-0-13-up-from-0-15-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Climb Bio Q3 EPS $(0.13) Up From $(0.15) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM"],"gpt_icon":0},{"id":"2483063343","title":"Climb Bio Inc Files for Mixed Shelf of up to $200 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483063343","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483063343?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:52","pubTimestamp":1731448356,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MJ1S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2483459057","title":"Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483459057","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483459057?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors. FDA Clearance of Investigational New Drug Application  for systemic lupus erythematosus . Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of Chemistry, Manufacturing and Controls. FDA Clearance of our IND for budoprutug in SLE.The U.S. Food and Drug Administration  has cleared the IND allowing Climb Bio to initiate a Phase 1b open label clinical trial of budoprutug in patients with active lupus. The trial is designed to evaluate the safety and impact of ascending dose regimens on the speed and depth of depletion of circulating B cells, the decline in production of pathogenic autoantibodies, and the nature of B cell subsets that are produced upon recovery of B cells. In addition, patients will be followed for changes in clinical outcomes.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HPitbdp9N5zE.42TwFDHng--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b6e600f3e302fa66aa6dc30453d5e383","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HPitbdp9N5zE.42TwFDHng--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b6e600f3e302fa66aa6dc30453d5e383"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/climb-bio-reports-third-quarter-210500406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CLYM","LU0149725797.USD","IE00B1BXHZ80.USD","LU1363072403.SGD","IE00BKVL7J92.USD","BK4139","LU0882574139.USD","IE00BHPRN162.USD","BK4006","BK4077","ITP","BK4199","LU0170899867.USD","LU0267386448.USD","LU0971096721.USD","SLE","IE00BZ1G4Q59.USD","CMC"],"gpt_icon":0},{"id":"2482778353","title":"Climb Bio Names Douglas Williams Board Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2482778353","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482778353?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:27","pubTimestamp":1731328067,"startTime":"0","endTime":"0","summary":"Climb Bio  said Monday it has named Douglas Williams as chair of its board.Williams will succeed Andrew Levin, who will continue as a board member, while Liam Ratcliffe will leave the board.Williams previously served as president of research and development at Sana Biotechnology. He was also previously chief executive at Codiak BioSciences.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4144","IE00BLSP4452.SGD","BK4585","LU1621767737.EUR","LU2237443622.USD","LU2237443978.SGD","IE00BBT3K403.USD","LU1621768115.EUR","LU0788109394.HKD","LU1621768206.USD","BK4139","BK4588","LU0122376428.USD","LU2384288077.EUR","CLYM","LU0070302665.USD","LU0320765489.SGD","IE00BLSP4239.USD","LU2237443382.USD","LU0208291251.USD","LU0368265418.SGD","WMB","IE00BN8TJ469.HKD","LU1621767810.EUR","LU2237443549.SGD"],"gpt_icon":0},{"id":"2482627200","title":"Climb Bio Appoints Douglas E. Williams, Ph.d., as Chair of the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2482627200","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482627200?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:00","pubTimestamp":1731326400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAC4Q3FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2482200106","title":"Climb Bio Inc - Andrew Levin to Remain on Board, Liam Ratcliffe Steps Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2482200106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482200106?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:00","pubTimestamp":1731326400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAC4Q3FC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139"],"gpt_icon":0},{"id":"2482001812","title":"Press Release: Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2482001812","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482001812?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:00","pubTimestamp":1731326400,"startTime":"0","endTime":"0","summary":"WELLESLEY, Mass., Nov. 11, 2024  -- Climb Bio, Inc.  today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine, Enbrel, Adcetris, Tecfidera, Alprolix, Eloctate and Spinraza. As a CEO, he has successfully guided both private and public companies from development to commercialization and has overseen multiple successful mergers.Dr. Williams added: \"I am honored to be joining Climb Bio's Board at this exciting time as they work to advance budoprutug and build a leading immune-mediated disease foc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1621768206.USD","LU2237443978.SGD","R","WMB","IE00BBT3K403.USD","LU2237443549.SGD","LU0070302665.USD","LU0788109394.HKD","BK4588","LU1621767737.EUR","LU0368265418.SGD","LU2237443622.USD","LU0320765489.SGD","LU1621767810.EUR","IE00BLSP4452.SGD","LU0208291251.USD","BK4585","LU2384288077.EUR","LU1621768115.EUR","IE00BN8TJ469.HKD","BK4022","IE00BLSP4239.USD","LU2237443382.USD","CLYM","BK4232","BK4144","LU0122376428.USD"],"gpt_icon":0},{"id":"2479970294","title":"Climb Bio to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2479970294","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479970294?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:00","pubTimestamp":1730372400,"startTime":"0","endTime":"0","summary":"WELLESLEY, Mass., Oct. 31, 2024  -- Climb Bio, Inc. , announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 11-12, 2024. Stifel 2024 Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 18-19, 2024. 7th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: December 3-5, 2024. The presentations will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at climbbio.com.About Climb Bio, Inc. Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HPitbdp9N5zE.42TwFDHng--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b6e600f3e302fa66aa6dc30453d5e383","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HPitbdp9N5zE.42TwFDHng--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b6e600f3e302fa66aa6dc30453d5e383"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/climb-bio-present-upcoming-investor-110000381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CLYM"],"gpt_icon":0},{"id":"2475421576","title":"Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2475421576","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475421576?lang=en_us&edition=fundamental","pubTime":"2024-10-15 19:00","pubTimestamp":1728990001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nTUA4DRGYK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CLYM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-09-13","symbol":"CLYM","fiscalQuarterEnding":"2021/06","expectedEps":-2.3,"name":null,"time":"","type":"earning","dateTimestamp":1631505600000,"reportTimeType":"","actualEps":-3.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CLYM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CLYM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1733198400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CLYM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CLYM","date":"2025-04-24","current":-1.223555,"percent":0.852941,"low":-5.682799,"twenty":-3.619939,"median":-1.876998,"eighty":-1.297365,"high":-1.031804,"avg":-2.428947,"sd":1.343581,"marketCap":90417029},"quantilePoints":[{"date":"2024-10-04","current":-5.327624,"twenty":-5.327624,"median":-5.327624,"eighty":-5.327624,"marketCap":342006831},{"date":"2024-10-11","current":-5.369409,"twenty":-5.463426,"median":-5.390302,"eighty":-5.369409,"marketCap":344689237},{"date":"2024-10-18","current":-5.076912,"twenty":-5.494765,"median":-5.390302,"eighty":-5.327624,"marketCap":325912392},{"date":"2024-10-25","current":-4.85754,"twenty":-5.463426,"median":-5.327624,"eighty":-5.014234,"marketCap":311829757},{"date":"2024-10-31","current":-4.094958,"twenty":-5.404927,"median":-5.238831,"eighty":-4.776059,"marketCap":262875838},{"date":"2024-11-08","current":-3.677105,"twenty":-5.390302,"median":-5.014234,"eighty":-4.074065,"marketCap":236051773},{"date":"2024-11-15","current":-3.107258,"twenty":-5.373588,"median":-4.888879,"eighty":-3.806639,"marketCap":214779913},{"date":"2024-11-22","current":-2.917613,"twenty":-5.335981,"median":-4.293438,"eighty":-3.619939,"marketCap":201671280},{"date":"2024-11-29","current":-3.141297,"twenty":-5.327624,"median":-4.220314,"eighty":-3.127681,"marketCap":217132744},{"date":"2024-12-06","current":-2.830085,"twenty":-5.277482,"median":-3.974826,"eighty":-3.040153,"marketCap":195621141},{"date":"2024-12-13","current":-2.742557,"twenty":-5.237786,"median":-3.781569,"eighty":-2.995417,"marketCap":189571003},{"date":"2024-12-20","current":-1.896449,"twenty":-5.13959,"median":-3.671882,"eighty":-2.96235,"marketCap":131086332},{"date":"2024-12-27","current":-2.207661,"twenty":-5.051841,"median":-3.301766,"eighty":-2.921503,"marketCap":152597935},{"date":"2025-01-03","current":-2.013153,"twenty":-5.003788,"median":-3.151022,"eighty":-2.57139,"marketCap":139153183},{"date":"2025-01-10","current":-1.818646,"twenty":-4.962003,"median":-3.124277,"eighty":-2.236837,"marketCap":125708431},{"date":"2025-01-17","current":-1.954801,"twenty":-4.920218,"median":-3.063494,"eighty":-2.032604,"marketCap":135119757},{"date":"2025-01-24","current":-1.770019,"twenty":-4.870076,"median":-3.005142,"eighty":-1.952856,"marketCap":122347243},{"date":"2025-01-31","current":-1.876998,"twenty":-4.531614,"median":-2.995417,"eighty":-1.91979,"marketCap":129741856},{"date":"2025-02-07","current":-1.701941,"twenty":-4.324777,"median":-2.96624,"eighty":-1.892559,"marketCap":117641580},{"date":"2025-02-14","current":-1.546335,"twenty":-4.251653,"median":-2.932201,"eighty":-1.865328,"marketCap":106885778},{"date":"2025-02-21","current":-1.400454,"twenty":-4.228671,"median":-2.873849,"eighty":-1.840042,"marketCap":96802214},{"date":"2025-02-28","current":-1.351828,"twenty":-4.1451,"median":-2.528598,"eighty":-1.818646,"marketCap":93441026},{"date":"2025-03-07","current":-1.429631,"twenty":-4.03228,"median":-2.256288,"eighty":-1.756403,"marketCap":98818927},{"date":"2025-03-14","current":-1.293475,"twenty":-3.971692,"median":-2.18821,"eighty":-1.542445,"marketCap":89407600},{"date":"2025-03-21","current":-1.244848,"twenty":-3.871407,"median":-2.022879,"eighty":-1.474368,"marketCap":86046412},{"date":"2025-03-28","current":-1.159638,"twenty":-3.794104,"median":-1.954801,"eighty":-1.429631,"marketCap":85693751},{"date":"2025-04-04","current":-1.050066,"twenty":-3.724618,"median":-1.940213,"eighty":-1.381004,"marketCap":77596704},{"date":"2025-04-11","current":-1.059197,"twenty":-3.680923,"median":-1.925625,"eighty":-1.357663,"marketCap":78271458},{"date":"2025-04-17","current":-1.150507,"twenty":-3.672927,"median":-1.896449,"eighty":-1.324596,"marketCap":85018997},{"date":"2025-04-24","current":-1.223555,"twenty":-3.619939,"median":-1.876998,"eighty":-1.297365,"marketCap":90417029}],"updateTime":1745635102825}}}